Patient Condition
Retired technology company executives will develop mild cognitive impairment in 2023. Mayo Clinic assessment showed an MMSE score of 22 points, positive for amyloid PET, and tau PET showed early tau deposition, consistent with indications for Donanemab treatment.
Treatment Timeline
| Phase | Details | Date |
|---|
| Accurate assessment and risk stratification | | |
| Semorinemab (anti-tau antibody) treatment | | |
| Joint cognitive rehabilitation + aerobic exercise | | |
| Maintenance treatment and cognitive function protection | | |
Treatment Outcome
| before | MMSE score 22 points, mild cognitive impairment, decreased work efficiency |
|---|
| after | MMSE score was 27 points (improvement by 5 points), amyloid was completely eliminated, and cognitive function was significantly improved |
|---|
| highlight | Amyloid protein was completely eliminated, cognitive function was significantly improved, and the course of treatment was completed |
|---|